ANTARES PHARMA INC.
ANTARES PHARMA INC.
Apertura: -
Variazione: -
Volumi: -
Minimo: -
Massimi: -
Distanza Mas/Min: -
Tipologia: Azioni
Ticker: ATRS
ISIN:

ANTARES PHARMA INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Antares Pharma, Inc. - ATRS

  • 82

Kuznicki Law PLLC is investigating the proposed sale of Antares Pharma, Inc. (NasdaqCM: ATRS) to Halozyme Therapeutics, Inc. (NasdaqGS: HALO). Under the terms of the proposed transaction, shareholders of Antares will receive only $5.60 in cash for each share of Antares that they own.

If you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, contact us toll free at 833-938-0905, via email ([email protected]), or visit https://kclasslaw.com/cases/ma/nasdaqcm-atrs/ to learn more.

Please note that the merger is structured as a tender offer, such that time may be of the essence.

Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005869/en/

Business Wire
Business Wire
Business Wire, filiale del gruppo Berkshire Hathaway dal 2006, è il leader mondiale nella distribuzione di comunicati stampa e comunicazione normativa e aziendale. I professionisti della comunicazione e del marketing si affidano a Business Wire per la distribuzione integrale e simultanea dei loro comunicati, foto e video alle agenzie stampa, sistemi d’informazione professionale, siti internet, media, giornalisti, blogger, analisti e investitori di tutto il mondo.